News
-
2020-05 29MORE
Latest Clinical Trial Results for Subcutaneous PD-L1 Antibody Envafolimab（KN035）Published on ASCO 2020 Annual Meeting
Beijing, China, May 29, 2020 - 3D Medicines, Inc.，a clinical stage biopharmaceutical company focusing on the development and commercialization of differentiated next-generation immuno-oncology drugs, today published the latest clinical trial results for Subcutaneous PD-L1 Antibody Envafolimab（KN035）on the 2020 annual meeting of American Society of Clinical Oncology (ASCO), under the title of “Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency”.
-
2020-05 29MORE
3D Medicines Announced Clinical Trial Data for Subcutaneous PD-L1 Antibody KN035 Would Be Published on ASCO 2020 Annual Meeting
Beijing, China, May 29, 2020 - 3D Medicines announced that the data from two clinical trials on Envafolimab (KN035) will be published on the 2020 annual meeting of American Society of Clinical Oncology (ASCO).
-
2020-03 30MORE
3D Medicines, Simcere and Alphamab Oncology Announced Partnership to Develop and Commercialize Subcutaneous PD-L1 Antibody for Cancer Indications in Mainland China
Beijing, China, March 30, 2020 – 3D Medicines announced that 3D Medicines (Beijing) Co., Ltd., a wholly-owned subsidiary of 3D Medicines, Inc., has established strategic partnership with Simcere Pharmaceuticals and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. （“Jiangsu Alphamab”）to advance the development and commercialization of Envafolimab (KN035), a checkpoint inhibitor for programmed cell death ligand-1 (PD-L1), for the treatment of cancer indications in mainland China.
-
2020-01 18MORE
PD-L1 Antibody Envafolimab（KN035）Granted Orphan Drug Designation by FDA
January 18, 2020 – 3D Medicines, Inc. (“3D Medicines”）and Alphamab Oncology (stock code: 9966.HK) (“Alphamab”) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to PD-L1 antibody KN035 for the treatment of biliary tract cancer (BTC).
-
2019-12 20MORE
3D Medicines, Alphamab and TRACON Reached a Three-way Collaboration to Advance the Clinical Development and Commercialization of KN035, a PD-L1 Single Domain Antibody, in Soft Tissue Sarcoma in North America
December 20, 2019 – 3D Medicines, Inc. (“3D Medicines”) announced that it has signed a collaboration agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (“Alphamab”), a wholly owned subsidiary of Alphamab Oncology (Stock code: 9966.HK) and TRACON Pharmaceuticals (“TRACON”) for the clinical development and commercialization of KN035, a PD-L1 single-domain antibody, in soft tissue sarcoma in North America.
